$830 Bn Artemisinin Combination Market - Global Outlook & Forecast Report 2017-2026

News provided by

Jan 31, 2019, 16:00 ET

DUBLIN, Jan. 31, 2019 /PRNewswire/ --

The "Artemisinin Combination - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Global Artemisinin Combination Therapy (ACT) market accounted for $338.80 billion in 2017 and is expected to reach $830.98 billion by 2026 growing at a CAGR of 10.5% during the forecast period.

Rising pipeline for new anti-malarial drugs, growing demand for artemisinin combination therapy (ACT) and increasing government initiatives are few factors propelling for the growth of the market. However, limited number of manufacturers globally acts as a hindrance for the market growth.

Based on type, Artesunate-Mefloquine is a lucrative market for Artemisinin Combination Therapy (ACT) due to its quick spread of resistance, mediated mainly by a raise in copy number and expression of the P. falciparum multi-drug resistance (MDR) gene. This improves bioavailability and reduces vomiting. There is no formulation of mefloquine for children. Regardless of earlier restrictions there is no cause to withhold mefloquine for young children. Limited information recommends that mefloquine is perhaps secure in pregnancy.

By geography, Middle East and Africa held the largest market share in the artemisinin combination therapy owing to have large number of production base of artemisinin herbs and growing demand in malaria endemic countries which are contributing to the expansion of the market in MEA. Though African countries, where the occurrence of malaria is high, so they have amplified malaria control strategies, efficient treatment and control, but it still presents a huge logistical difficulty. As numerous at-risk people survive in extreme poverty in isolated areas, WHO and other organizations are working on completely eradicating it in Africa and thus, over the coming years, the adoption rate of ACT is further expected to boost.

What our report offers:

Market share assessments for the regional and country level segments
Market share analysis of the top industry players
Strategic recommendations for the new entrants
Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Key Topics Covered:

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.5 Research Sources

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Futuristic Market Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Artemisinin Combination Therapy (ACT) Market, By Type
5.1 Introduction
5.2 Artesunate-Sulfadoxine-Pyrimethamine
5.3 Artesunate-Mefloquine
5.4 Artesunate-Pyronaridine
5.5 Artemether-Lumefantrine
5.6 Artesunate-Amodiaquine
5.7 Dihydroartemisinin-Piperaquine

6 Global Artemisinin Combination Therapy (ACT) Market, By Geography
6.1 Introduction
6.2 North America
6.3 Europe
6.4 Asia Pacific
6.5 South America
6.6 Middle East & Africa

7 Key Developments
7.1 Agreements, Partnerships, Collaborations and Joint Ventures
7.2 Acquisitions & Mergers
7.3 New Product Launch
7.4 Expansions
7.5 Other Key Strategies

8 Company Profiling
8.1 KPC Pharmaceuticals, Inc.
8.2 Shanghai Fosun Pharmaceutical Industrial Development Company Limited
8.3 Sanofi
8.4 Desano Holdings Ltd.
8.5 Calyx Chemicals and Pharmaceuticals Limited
8.6 Mylan N.V.
8.7 Novartis AG
8.8 Denk Pharma GmbH & Co. KG
8.9 Hovid Berhad
8.10 Ipca Laboratories Limited
8.11 Cipla Limited
8.12 Aspen Pharmacare Holdings Limited

For more information about this report visit https://www.researchandmarkets.com/research/6gr346/830_bn?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets